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OBJECTIVES This study was designed to assess whether use of enoxaparin during percutaneous coronary
intervention (PCI) increased bleeding compared with unfractionated heparin, in addition to
background therapy with eptifibatide.
BACKGROUND Data supporting the benefits of enoxaparin and the glycoprotein IIb/IIIa inhibitor eptifibatide
evolved in parallel. Information on combining these two classes of medications is limited.
METHODS A total of 261 patients undergoing elective or urgent PCI were randomized to either
eptifibatide plus enoxaparin or eptifibatide plus unfractionated heparin.
RESULTS The primary end point of the study, the bleeding index (change in hemoglobin corrected for
blood transfusions), was 0.8 in the patients randomized to enoxaparin and 1.1 in patients
randomized to unfractionated heparin (p  0.15). The rate of vascular access site complica-
tions was 9.3% in the enoxaparin arm versus 9.8% in the unfractionated heparin arm (p 
NS). The rate of bleeding complications was not significantly different between the two arms
of the study, including in those patients who received vascular closure devices. The rate of
angiographic complications was 6.3% in the enoxaparin group and 6.2% in the unfractionated
heparin group (p  NS). Similarly, there were no significant differences in the composite of
death, myocardial infarction, or urgent target vessel revascularization at 48 h or 30 days.
CONCLUSIONS Compared with unfractionated heparin plus eptifibatide, the combination of enoxaparin plus
eptifibatide is not associated with an excess of bleeding or vascular complications, including
in those receiving closure devices. Despite no monitoring of anticoagulation activity with
enoxaparin, there was no apparent increase in angiographic or clinical complications. (J Am
Coll Cardiol 2003;41:20–5) © 2003 by the American College of Cardiology Foundation
The low-molecular-weight heparin enoxaparin has been
shown to improve outcomes in patients with acute coronary
syndromes (1–7). Enoxaparin has also been shown to be
cost-effective in this setting compared with intravenous (IV)
unfractionated heparin (8). However, given the current lack
of point-of-care monitoring for the extent of anticoagula-
tion with low-molecular-weight heparin, concerns about
integrating enoxaparin into the catheterization laboratory
and the potential for thrombosis or abrupt closure persist
and have limited its use. Furthermore, enoxaparin evolved in
parallel, but separately, with the platelet glycoprotein (GP)
IIb/IIIa inhibitor era. While there is abundant evidence
regarding the efficacy of GP IIb/IIIa inhibitors such as
eptifibatide and tirofiban in acute coronary syndromes
(9–13) and abciximab and eptifibatide in the catheterization
laboratory (14–19), there is no guidance in combining
enoxaparin use with eptifibatide. In particular, it is unclear
whether an anticoagulation assay would be needed to select
optimal doses of enoxaparin when used with eptifibatide. In
some tertiary care centers, because over 50% of coronary
interventions involve the use of GP IIb/IIIa inhibitors, the
limited data on bleeding risk from combination therapy has
been especially troubling and has limited the utilization of
enoxaparin. The combination of enoxaparin, GP IIb/IIIa
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inhibitors, and vascular closure devices has raised additional
concerns regarding the potential for groin complications.
Only nonrandomized registry experience has been available
thus far to assess the safety of combination therapy with
abciximab and enoxaparin in comparison with historical
data (20). Therefore, this study was performed as the first
randomized trial of the safety and feasibility of combined
enoxaparin with eptifibatide during percutaneous coronary
revascularization.
METHODS
The Coronary Revascularization Using Integrilin and Single
bolus Enoxaparin (CRUISE) trial was conducted at 12
medical centers and enrolled a total of 261 patients under-
going elective or urgent percutaneous coronary intervention
(PCI). Written informed consent was obtained from all
participants, and institutional review board approval was
given. All patients received 325 mg of daily aspirin; patients
treated with stents received clopidogrel 75 mg daily for at
least 30 days, with a loading dose allowed at the operator’s
discretion. All patients received eptifibatide therapy before
device activation. Patients were assigned in an open-label
fashion by central telephone randomization to receive IV
enoxaparin or unfractionated heparin at the time of PCI.
Patients were included if they were males or nonpregnant
females at least 18 years of age who were to undergo elective
or urgent percutaneous coronary revascularization. Exclu-
sion criteria included: acute myocardial infarction within the
24 h before randomization; administration of any IV un-
fractionated heparin within 4 h or low-molecular-weight
heparin within 12 h before randomization; treatment with
any parenteral or oral platelet GP IIb/IIIa inhibitor within
the previous 30 days before study randomization; chronic
warfarin therapy; thrombolytic therapy within 48 h before
randomization; history of bleeding diathesis; evidence of
active abnormal bleeding within the previous 30 days; severe
hypertension (systolic blood pressure 200 mm Hg or
diastolic blood pressure 110 mm Hg) not adequately
controlled on antihypertensive therapy; major surgery
within the preceding 6 weeks; history of stroke within 30
days of randomization; any history of hemorrhagic stroke;
concurrent or planned administration of another parenteral
or oral GP IIb/IIIa inhibitor or warfarin within 30 days after
randomization; platelet count 100,000 mm3; serum cre-
atinine 2.0 mg/dl; dependency on renal dialysis; known
hypersensitivity to any component of eptifibatide or heparin
or porcine products; history of heparin-induced thrombo-
cytopenia; recent or planned spinal puncture; or participa-
tion in another study of experimental therapy within 30
days.
Dosing of medications. Eptifibatide was administered at
the time of the PCI utilizing the Enhanced Suppression of
the Platelet IIb/IIIa Receptor with Integrilin Therapy
double-bolus regimen (21). Eptifibatide was given as a 180
g/kg IV bolus before PCI, followed by a 2 g/kg/min
infusion, with a second bolus of 180 g/kg given 10 min
later. The infusion was continued through intervention until
18 to 24 h after the PCI or until hospital discharge,
whichever came first. Patients randomized to enoxaparin
were given a dose of 0.75 mg/kg intravenously before PCI.
Patients randomized to unfractionated heparin received a
bolus of 60 IU/kg intravenously before PCI, with additional
boluses of 10 to 20 IU/kg administered as necessary to
achieve an activated clotting time (ACT) 200 s.
Sheath management. For patients randomized to unfrac-
tionated heparin, the sheath could be removed 2 to 4 h after
the last administered dose of unfractionated heparin, after
documenting a decline in activated partial thromboplastin
time to 45 s or ACT to 150 s. For patients randomized
to enoxaparin, the sheath could be removed 4 h after the
bolus of enoxaparin. The use of Food and Drug
Administration-approved vascular closure devices was per-
mitted at any time after the PCI.
End points. Blood samples for creatine kinase (CK) and
CK-MB were drawn at baseline (before PCI) and 6, 12, 18,
and 24 h later. Hemoglobin and platelet counts were
measured and electrocardiogram performed at baseline and
24 h after PCI (or at hospital discharge).
The primary end point was the bleeding index, defined as
the fall in hemoglobin (g/dl) over the first 24 h, adjusted for
whole blood or red blood cell transfusions (prehemoglobin 
post hemoglobin  units transfused) (22).
Other safety parameters assessed included: major and
minor bleeding by the Global Utilization of Streptokinase
and Tissue Plasminogen Activator for Occluded Coronary
Arteries criteria (23); major and minor bleeding by the
Thrombolysis In Myocardial Infarction (TIMI) criteria
(24); need for transfusion; thrombocytopenia (defined as
platelet count 100 K, 50 K, 20 K, or 30% decrease);
groin complications (hematoma 5 cm in diameter or bleed-
ing requiring medical intervention, vascular repair, or lead-
ing to prolonged hospitalization); or hemorrhagic stroke at
48 h.
Efficacy end points were death, myocardial infarction
(defined as new Q waves of 0.04 s in at least two leads or
CK-MB 3 the upper limit of normal after PCI and at
least 50% above the previous nadir), or urgent revascular-
ization (PCI or coronary artery bypass grafting) at 48 h, 7
days, and 30 days. Angiographic complications (major
dissection, thrombus formation, abrupt vessel closure, side-
branch closure) were recorded by the operator.
Abbreviations and Acronyms
ACT  activated clotting time
CK  creatine kinase
CRUISE  Coronary Revascularization Using Integrilin
and Single bolus Enoxaparin trial
GP  glycoprotein
IV  intravenous
PCI  percutaneous coronary intervention
TIMI  Thrombolysis In Myocardial Infarction
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Statistical analysis. Based on prior studies of eptifibatide
in PCI, the mean expected bleeding index in the unfrac-
tionated heparin group was 2.0  2.6. Therefore, a sample
size of 250 patients (125 per arm) was calculated to provide
83% power to detect a 50% reduction from the control rate
of 2.0 in the primary end point using the Wilcoxon
rank-sum test at the   0.05 significance level. All
statistical tests were two-sided. Clinical efficacy data were
analyzed using a Fisher exact test.
RESULTS
The baseline characteristics of the patients in the enoxaparin
and unfractionated heparin arms are listed in Table 1. Of
the 129 patients randomized to enoxaparin, 126 underwent
PCI; of the 132 patients randomized to unfractionated
heparin, 130 underwent PCI. Stents were placed in 86.5%
and 85.4% of the enoxaparin and unfractionated heparin
arms, with thienopyridine pretreatment in 94.6% and
93.8%, respectively. There were no significant differences in
baseline characteristics between the two randomized groups.
The median maximal procedural ACT in the unfractionated
heparin group was 274 (interquartile range: 241, 317).
There was no significant difference in the mean bleeding
index, the primary end point of the study, between the
patients randomized to unfractionated heparin versus enox-
aparin, (1.1 vs. 0.8; p  0.15). There were no blood
transfusions within 24 h in either arm of the study; thus, the
bleeding index herein represents the drop in hemoglobin.
Likewise, there were no significant differences in major or
minor bleeding complications (Table 2). There were no
cases of severe thrombocytopenia with platelets 50 K in
either arm.
The proportion of patients receiving closure devices was
42.1% in the enoxaparin patients and 33.8% in the unfrac-
tionated heparin group. The median time to sheath removal
in both groups was 4.4 h. Rates of vascular complications
did not differ between the treatment arms in the overall
population (Table 3) or in those receiving closure devices
(Tables 4 and 5). In Table 5, of the 53 patients who received
closure devices, 5 patients had unresolved TIMI bleeding
severity and, hence, were not included in Table 4, leaving 48
patients for analysis. Similarly, 6 of the 44 patients who
received closure devices had unresolved TIMI bleeding
severity, leaving 38 patients for analysis.
There were no apparent differences in angiographic
complications (Table 6). Similarly, there were no apparent
differences in the rate of clinical events at 48 h (Table 7) or
at 30 days. Between 48 h and 30 days, two additional
patients required urgent target vessel revascularization in the
enoxaparin group.
Table 1. Baseline Characteristics of the Patients Randomized to Enoxaparin Plus Eptifibatide
Versus Unfractionated Heparin Plus Eptifibatide
Enoxaparin
 Eptifibatide
(N  129)
Unfractionated Heparin
 Eptifibatide
(N  132) p Value
Age (yrs) 63.3  10.3 63.7  10.2 0.78
Weight (kg) 88.2  14.9 88.7  17.4 0.82
Female gender (%) 23.3 24.2 0.89
Prior MI (%) 26.4 31.8 0.34
Prior PCI (%) 44.2 45.5 0.84
Prior CABG (%) 29.5 25.8 0.58
Diabetes (%) 27.9 31.1 0.59
Hypertension (%) 67.4 68.9 0.89
Hypercholesterolemia (%) 70.5 71.2 1.00
Any smoking (%) 65.1 65.9 0.90
Acute coronary syndrome (%) 46.8 44.6 0.80
CABG  coronary artery bypass grafting; MI  myocardial infarction; PCI  percutaneous coronary intervention.
Table 2. Bleeding Complications
Enoxaparin
 Eptifibatide
(N  129)
Unfractionated Heparin
 Eptifibatide
(N  132) p Value
Mean bleeding index 0.8 1.1 0.15
TIMI major bleeding (%) 2.5 1.6 0.68
TIMI major  minor bleeding (%) 4.1 10.5 0.08
GUSTO severe bleeding (%) 0 0 N/A
GUSTO moderate bleeding (%) 0 2.3 0.25
GUSTO mild bleeding (%) 14.0 14.4 1.00
Thrombocytopenia (100,000/mm3) (%) 1.6 1.6 1.00
GUSTO  Global Utilization of Streptokinase and Tissue Plasmogen Activator for Occluded Coronary Arteries trial; TIMI 
Thrombolysis In Myocardial Infarction.
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DISCUSSION
Strong data exist supporting the use of GP IIb/IIIa inhib-
itors and low-molecular-weight heparin as individual drug
classes. However, data are more limited regarding the
combination of these two forms of antithrombotic therapy.
Concerns about safety and integration with the catheteriza-
tion laboratory have hampered the use of a strategy of
combining these two potentially complementary forms of
thrombus prevention.
The CRUISE study was designed to assess if combina-
tion therapy with enoxaparin and eptifibatide posed a
bleeding hazard when compared with eptifibatide plus
unfractionated heparin. The bleeding index, a sensitive
metric of blood loss, was designated as the primary end
point of the study. No significant difference was found in
the bleeding index, which was similarly low in both arms of
the study. Thus, despite concerns that enoxaparin, especially
when combined with GP IIb/IIIa inhibition, may increase
the rate of catheterization-related bleeding, enoxaparin plus
eptifibatide appeared to be safe. Furthermore, although
there was no monitoring of the anticoagulant effect of
enoxaparin during PCI, we observed no increase in angio-
graphic complications or a detectable increase in adverse
clinical events.
During contemporary PCI, a large proportion of patients
receive stents and pretreatment with clopidogrel before the
procedure, practices that were reflected in the CRUISE
study. Despite treatment with aspirin, clopidogrel, enoxapa-
rin, and eptifibatide, blood loss in the CRUISE study was
not significantly higher than in other studies of antithrom-
botic therapy in PCI. Additionally, the use of closure
devices did not appear to be associated with a bleeding
excess. Some interventional cardiologists have expressed
concerns about using low-molecular-weight heparin in pa-
tients receiving a closure device if it ultimately does not
deploy appropriately and obtain hemostasis; unlike unfrac-
tionated heparin, the activity of enoxaparin is only partially
reversed by protamine. While these concerns may be valid,
in the CRUISE population, there was no excess of bleeding
or vascular complications with the combination of enoxapa-
rin and eptifibatide with either suture-based or collagen
closure devices.
Prior studies of enoxaparin in PCI have consisted only of
nonrandomized registries. The National Investigators Col-
laborating on Enoxaparin (NICE)-1 registry established
that a dose of 1 mg/kg of IV enoxaparin could be used
during PCI, while the NICE-4 registry established the
feasibility of 0.75 mg/kg of enoxaparin with abciximab in
that setting (20). The NICE-3 registry combined enoxapa-
rin and GP IIb/IIIa inhibition during the medical phase of
therapy in patients presenting with acute coronary syn-
dromes, continuing these agents through the time of PCI.
While these observational studies supported in concept the
integration of enoxaparin and GP IIb/IIIa inhibition, with
safety outcomes comparable to historical controls, they did
not provide direct randomized evidence showing equivalent
safety. In this context, the CRUISE trial provides the first
randomized experience of enoxaparin versus unfractionated
heparin with background therapy including eptifibatide,
confirming the safety experience inferred from prior registry
data. While an equivalent degree of safety and efficacy in
conjunction with greater ease of administration may be
sufficient to justify the use of enoxaparin instead of unfrac-
tionated heparin, there are also data to suggest that enox-
aparin may be synergistic with GP IIb/IIIa inhibition in
reducing platelet activation and, thus, superior to unfrac-
Table 3. Vascular Complications
Enoxaparin
 Eptifibatide
(N  129)
Unfractionated
Heparin
 Eptifibatide
(N  132) p Value
Hematoma (%) 3.9 6.8 0.41
Re-bleed after
hemostasis (%)
5.4 3.8 0.19
Pseudoaneurysm (%) 0.8 0.8 1.00
AV fistula (%) 0 0 N/A
Total (%) 9.3 9.8 1.00
AV  arteriovenous.
Table 4. Bleeding Complications in Those Receiving Closure Devices
Enoxaparin
 Eptifibatide
(N  48)
Unfractionated Heparin
 Eptifibatide
(N  38) p Value
TIMI major bleeding (%) 0 2.6 0.44
TIMI minor bleeding (%) 0 7.9 0.08
TIMI major access site bleeding (%) 0 2.6 0.44
TIMI minor access site bleeding (%) 0 5.3 0.19
TIMI  Thrombolysis In Myocardial Infarction.
Table 5. Vascular Complications in Those Receiving
Closure Devices
Enoxaparin
 Eptifibatide
(N  53)
Unfractionated
Heparin
 Eptifibatide
(N  44) p Value
Hematoma (%) 7.5 2.3 0.37
Re-bleed after
hemostasis (%)
5.7 6.8 1.00
Pseudoaneurysm (%) 0 0 N/A
AV fistula (%) 0 0 N/A
Total (%) 13.2 9.1 0.75
AV  arteriovenous.
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tionated heparin (25,26). Enoxaparin prevents release of von
Willebrand factor, a property not shared by unfractionated
heparin (27). The Superior Yield of the New Strategy of
Enoxaparin, Revascularization, and Glycoprotein IIb/IIIa
Inhibitors (SYNERGY) trial will randomize a large cohort
of patients with acute coronary syndromes to either unfrac-
tionated heparin or enoxaparin in the setting of unstable
angina, with a sizable proportion of patients continuing on
to PCI, thus permitting definitive assessment of the relative
efficacy of these two thrombin inhibitors in both the medical
and revascularization phases of treatment.
Study limitations. This study was only powered for differ-
ences in the bleeding index between enoxaparin and unfrac-
tionated heparin for patients receiving concomitant GP
IIb/IIIa inhibition. The observed rate of blood loss as
reflected in the bleeding index was lower than expected
based upon prior data, thus limiting the statistical power of
our study. Furthermore, this study, although randomized,
was not double-blinded, in order to limit complexity and
facilitate rapid enrollment in this pilot. Therefore, end
points such as access site bleeding could have potentially
been influenced by investigator bias. However, at the time
of this study, there was bias against enoxaparin among
interventional cardiologists, not in favor of it. Moreover,
this trial was not powered to examine potential differences
in efficacy, as such a trial would have required several
thousand patients. While there was no apparent difference
in angiographic complications between the enoxaparin and
unfractionated heparin arms, all patients received eptifi-
batide. Therefore, the results of this study should not be
extrapolated to patients not receiving GP IIb/IIIa antago-
nists. While there is a large body of data supporting the use
of enoxaparin in patients with an acute coronary syndrome,
this study does not specifically address the issue of giving IV
enoxaparin at the time of PCI in patients who are already
therapeutic on subcutaneous enoxaparin. However, such
dosing algorithms are being developed at several centers and
used in the ongoing SYNERGY trial.
Conclusions. The use of enoxaparin instead of unfraction-
ated heparin with concomitant GP IIb/IIIa inhibition with
eptifibatide during elective or urgent PCI does not lead to
an increase in bleeding, including minor degrees of blood
loss as measured by the sensitive bleeding index. Further-
more, there is no apparent loss of efficacy with the substi-
tution of enoxaparin in place of unfractionated heparin in
this setting. Definitive assessment of the role of enoxaparin
is underway in large randomized clinical trials spanning the
continuum of care of patients with acute ischemic syn-
dromes.
Reprint requests and correspondence: Dr. Deepak L. Bhatt,
Cleveland Clinic Foundation, Department of Cardiovascular
Medicine, Desk F25, 9500 Euclid Avenue, Cleveland, Ohio
44195. E-mail: bhattd@ccf.org.
REFERENCES
1. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-
molecular-weight heparin with unfractionated heparin for unstable
coronary artery disease: Efficacy and Safety of Subcutaneous Enoxapa-
rin in Non–Q-Wave Coronary Events Study Group. N Engl J Med
1997;337:447–52.
2. Antman EM. TIMI 11B: enoxaparin versus unfractionated heparin for
unstable angina or non–/Q-wave myocardial infarction: a double-
blind, placebo-controlled, parallel-group, multicenter trial. Rationale,
study design, and methods. Thrombolysis In Myocardial Infarction
(TIMI) 11B trial investigators. Am Heart J 1998;135:S353–60.
3. TIMI 11A Investigators. Dose-ranging trial of enoxaparin for unstable
angina: results of TIMI 11A. J Am Coll Cardiol 1997;29:1474–82.
4. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:
688–98.
5. Futterman LG, Lemberg L. Low-molecular-weight heparin: an anti-
thrombotic agent whose time has come. Am J Crit Care 1999;8:
520–3.
6. Purcell H, Fox KM. Current roles and future possibilities for low-
molecular-weight heparins in unstable angina. Eur Heart J 1998;19
Suppl K:K18–23.
7. Huang JN, Shimamura A. Low-molecular-weight heparins. Hematol
Oncol Clin North Am 1998;12:1251–81.
8. Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of
low-molecular-weight heparin (enoxaparin) versus unfractionated hep-
arin in acute coronary syndrome patients: results from the ESSENCE
randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in
Non–Q-Wave Coronary Events (unstable angina or non–Q-wave
myocardial infarction). Circulation 1998;97:1702–7.
Table 6. Angiographic Complications
Enoxaparin
 Eptifibatide
(N  126)
Unfractionated Heparin
 Eptifibatide
(N  130) p Value
Major dissection (%) 2.4 4.6 0.50
Abrupt closure (%) 1.6 0.8 0.62
Thrombus formation (%) 0.8 0.8 1.00
No reflow (%) 0 0 N/A
Distal embolization (%) 0 0 N/A
Side-branch closure (%) 2.4 1.5 0.68
Total (%) 6.3 6.2 1.00
Table 7. Clinical End Points at 48 h
Enoxaparin
 Eptifibatide
(N  129)
Unfractionated Heparin
 Eptifibatide
(N  132) p Value
Death (%) 0 0 N/A
MI (%) 8.5 7.6 0.82
Urgent TVR (%) 0 0.8 1.0
Total (%) 8.5 7.6 0.82
MI  myocardial infarction; TVR  target vessel revascularization.
24 Bhatt et al. JACC Vol. 41, No. 1, 2003
Eptifibatide and Enoxaparin in PCI January 1, 2003:20–5
9. The PARAGON Investigators. International, randomized, controlled
trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or
both in unstable angina: Platelet IIb/IIIa Antagonism for the Reduc-
tion of Acute coronary syndrome events in a Global Organization
Network. Circulation 1998;97:2386–95.
10. The PRISM-PLUS Investigators. Inhibition of the platelet glycopro-
tein IIb/IIIa receptor with tirofiban in unstable angina and non–Q-
wave myocardial infarction: Platelet Receptor Inhibition in Ischemic
Syndrome Management in Patients Limited by Unstable Signs and
Symptoms (PRISM-PLUS). N Engl J Med 1998;338:1488–97.
11. The PRISM Investigators. A comparison of aspirin plus tirofiban with
aspirin plus heparin for unstable angina: Platelet Receptor Inhibition
in Ischemic Syndrome Management (PRISM) study. N Engl J Med
1998;338:1498–505.
12. The PURSUIT Investigators. Inhibition of platelet glycoprotein
IIb/IIIa with eptifibatide in patients with acute coronary syndromes:
Receptor Suppression Using Integrilin Therapy. N Engl J Med
1998;339:436–43.
13. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of
early invasive and conservative strategies in patients with unstable
coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor
tirofiban. N Engl J Med 2001;344:1879–87.
14. The EPISTENT Investigators. Randomised placebo-controlled and
balloon-angioplasty-controlled trial to assess safety of coronary stent-
ing with use of platelet glycoprotein IIb/IIIa blockade: Evaluation of
Platelet IIb/IIIa Inhibitor for STENTing. Lancet 1998;352:87–92.
15. The CAPTURE Investigators. Randomised placebo-controlled trial
of abciximab before and during coronary intervention in refractory
unstable angina: the CAPTURE study. Lancet 1997;349:1429–35.
16. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor
blockade and low-dose heparin during percutaneous coronary revas-
cularization. N Engl J Med 1997;336:1689–96.
17. The EPIC Investigators. Use of a monoclonal antibody directed
against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary
angioplasty: the EPIC investigation. N Engl J Med 1994;330:956–61.
18. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of
coronary intervention with antibody against platelet IIb/IIIa integrin
for reduction of clinical restenosis: results at six months: the EPIC
investigators. Lancet 1994;343:881–6.
19. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection
from myocardial ischemic events in a randomized trial of brief integrin
beta-3 blockade with percutaneous coronary intervention: EPIC in-
vestigator group (Evaluation of Platelet IIb/IIIa Inhibition for Pre-
vention of Ischemic Complication). JAMA 1997;278:479–84.
20. Kereiakes DJ, Fry E, Matthai W, et al. Combination enoxaparin and
abciximab therapy during percutaneous coronary intervention: “NICE
guys finish first.” J Invasive Cardiol 2000;12 Suppl A:1A–5A.
21. O’Shea JC, Hafley GE, Greenberg S, et al. Platelet glycoprotein
IIb/IIIa integrin blockade with eptifibatide in coronary stent interven-
tion: the ESPRIT trial: a randomized controlled trial. JAMA 2001;
285:2468–73.
22. Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L.
Identification and preliminary validation of predictors of major bleed-
ing in hospitalized patients starting anticoagulant therapy. Am J Med
1987;82:703–13.
23. The GUSTO Investigators. An international randomized trial com-
paring four thrombolytic strategies for acute myocardial infarction.
N Engl J Med 1993;329:673–82.
24. Rao AK, Pratt C, Berke A, et al. Thrombolysis In Myocardial
Infarction (TIMI) trial—phase I: hemorrhagic manifestations and
changes in plasma fibrinogen and the fibrinolytic system in patients
treated with recombinant tissue plasminogen activator and streptoki-
nase. J Am Coll Cardiol 1988;11:1–11.
25. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at
therapeutic concentrations and comparisons with a low-molecular-
weight heparin and with a direct thrombin inhibitor. Circulation
1998;97:251–6.
26. Cohen M, Theroux P, Weber S, et al. Evaluation of combination
therapy with tirofiban and enoxaparin in patients with unstable angina
and non–Q-wave myocardial infarction. Eur Heart J 1999;20:376.
27. Montalescot G, Collet JP, Lison L, et al. Effects of various anticoag-
ulant treatments on von Willebrand factor release in unstable angina.
J Am Coll Cardiol 2000;36:110–4.
25JACC Vol. 41, No. 1, 2003 Bhatt et al.
January 1, 2003:20–5 Eptifibatide and Enoxaparin in PCI
